Emcure Pharmaceuticals Receives USFDA Inspection Report; Facility Classified as VAI
Emcure Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) regarding an inspection of its formulations facility. The inspection, which took place between May 06, 2026, and May 15, 2026, at the company's location in G.I.D.C., Taluka - Sanand, Ahmedabad -382110, Gujarat, resulted in a classification of Voluntary Action Indicated (VAI).The USFDA inspection was conducted on the formulations facility located in Sanand, Ahmedabad. Following the review process, Emcure Pharmaceuticals confirmed that it has received the official Establishment Inspection Report from the...